SciSparc Ltd. Logo

SciSparc Ltd.

SPRC

(0.5)
Stock Price

0,21 USD

-64.08% ROA

-87.48% ROE

-0.02x PER

Market Cap.

536.077,00 USD

1% DER

0% Yield

-177.91% NPM

SciSparc Ltd. Stock Analysis

SciSparc Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

SciSparc Ltd. Fundamental Stock Analysis
# Analysis Rating
1 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

2 ROE

The stock's ROE indicates a negative return (-35.53%) on shareholders' equity, suggesting poor financial performance.

3 ROA

The stock's ROA (-44.02%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

4 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.7x) suggests it's overvalued, potentially making it an expensive investment.

5 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

6 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (-47) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

SciSparc Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

SciSparc Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

SciSparc Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

SciSparc Ltd. Revenue
Year Revenue Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 487.000 100%
2018 838.000 41.89%
2019 498.000 -68.27%
2020 550.000 9.45%
2021 1.069.000 48.55%
2022 1.347.000 20.64%
2023 3.628.000 62.87%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

SciSparc Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
2012 2.308.923
2013 1.334.960 -72.96%
2014 462.257 -188.79%
2015 238.494 -93.82%
2016 738.834 67.72%
2017 2.017.000 63.37%
2018 2.710.000 25.57%
2019 1.639.000 -65.34%
2020 649.000 -152.54%
2021 1.990.000 67.39%
2022 2.803.000 29%
2023 3.440.000 18.52%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

SciSparc Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 1.254.838
2013 567.695 -121.04%
2014 1.319.489 56.98%
2015 804.117 -64.09%
2016 1.290.490 37.69%
2017 3.736.000 65.46%
2018 5.811.000 35.71%
2019 2.397.000 -142.43%
2020 1.720.000 -39.36%
2021 3.643.000 52.79%
2022 5.378.000 32.26%
2023 9.804.000 45.14%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

SciSparc Ltd. EBITDA
Year EBITDA Growth
2012 -3.533.247
2013 -1.963.819 -79.92%
2014 -1.861.359 -5.5%
2015 -2.647.515 29.69%
2016 -2.032.704 -30.25%
2017 -5.747.000 64.63%
2018 -8.617.000 33.31%
2019 -3.734.000 -130.77%
2020 -2.592.000 -44.06%
2021 -5.741.000 54.85%
2022 -8.506.000 32.51%
2023 -10.328.000 17.64%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

SciSparc Ltd. Gross Profit
Year Gross Profit Growth
2012 0
2013 0 0%
2014 0 0%
2015 -3.089 100%
2016 0 0%
2017 481.999 100%
2018 691.000 30.25%
2019 319.000 -116.61%
2020 386.000 17.36%
2021 1.036.000 62.74%
2022 1.025.000 -1.07%
2023 1.292.000 20.67%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

SciSparc Ltd. Net Profit
Year Net Profit Growth
2012 -3.544.757
2013 59.440 6063.59%
2014 -1.850.829 103.21%
2015 -2.530.190 26.85%
2016 -1.990.329 -27.12%
2017 -6.244.000 68.12%
2018 -8.523.000 26.74%
2019 -5.362.000 -58.95%
2020 -3.507.000 -52.89%
2021 -5.801.000 39.54%
2022 -2.592.000 -123.8%
2023 -8.968.000 71.1%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

SciSparc Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -1
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 -1 100%
2019 -1 0%
2020 -2 100%
2021 -74 97.26%
2022 -15 -421.43%
2023 -23 36.36%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

SciSparc Ltd. Free Cashflow
Year Free Cashflow Growth
2012 -3.972.227
2013 -2.741.421 -44.9%
2014 -1.890.121 -45.04%
2015 -1.323.373 -42.83%
2016 -1.483.388 10.79%
2017 -4.623.000 67.91%
2018 -7.149.000 35.33%
2019 -4.697.000 -52.2%
2020 -4.307.000 -9.06%
2021 -5.096.000 15.48%
2022 -12.786.000 60.14%
2023 -2.654.000 -381.76%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

SciSparc Ltd. Operating Cashflow
Year Operating Cashflow Growth
2012 -3.953.490
2013 -2.740.273 -44.27%
2014 -1.889.608 -45.02%
2015 -1.322.349 -42.9%
2016 -1.479.228 10.61%
2017 -4.579.000 67.7%
2018 -7.132.000 35.8%
2019 -4.696.000 -51.87%
2020 -4.307.000 -9.03%
2021 -5.061.000 14.9%
2022 -7.917.000 36.07%
2023 -2.654.000 -198.3%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

SciSparc Ltd. Capital Expenditure
Year Capital Expenditure Growth
2012 18.737
2013 1.149 -1532.06%
2014 514 -123.78%
2015 1.025 49.9%
2016 4.160 75.38%
2017 44.000 90.55%
2018 17.000 -158.82%
2019 1.000 -1600%
2020 0 0%
2021 35.000 100%
2022 4.869.000 99.28%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

SciSparc Ltd. Equity
Year Equity Growth
2013 995.261
2014 -116.335 955.52%
2015 1.154.556 110.08%
2016 572.713 -101.59%
2017 8.389.000 93.17%
2018 77.000 -10794.81%
2019 14.000 -450%
2020 1.430.000 99.02%
2021 8.141.000 82.43%
2022 6.449.000 -26.24%
2023 9.587.000 32.73%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

SciSparc Ltd. Assets
Year Assets Growth
2013 1.691.026
2014 261.175 -547.47%
2015 1.665.360 84.32%
2016 1.244.735 -33.79%
2017 9.566.000 86.99%
2018 4.560.000 -109.78%
2019 1.154.000 -295.15%
2020 2.561.000 54.94%
2021 9.916.000 74.17%
2022 10.605.000 6.5%
2023 11.182.000 5.16%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

SciSparc Ltd. Liabilities
Year Liabilities Growth
2013 695.764
2014 377.510 -84.3%
2015 510.802 26.09%
2016 672.022 23.99%
2017 1.177.000 42.9%
2018 4.483.000 73.75%
2019 1.140.000 -293.25%
2020 1.131.000 -0.8%
2021 1.775.000 36.28%
2022 4.156.000 57.29%
2023 1.595.000 -160.56%

SciSparc Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
7.24
Net Income per Share
-12.89
Price to Earning Ratio
-0.02x
Price To Sales Ratio
0.19x
POCF Ratio
-0.01
PFCF Ratio
-0.09
Price to Book Ratio
0.01
EV to Sales
-0.53
EV Over EBITDA
0.29
EV to Operating CashFlow
0.26
EV to FreeCashFlow
0.26
Earnings Yield
-58.92
FreeCashFlow Yield
-10.98
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
74.52
Graham NetNet
10.4

Income Statement Metrics

Net Income per Share
-12.89
Income Quality
1.15
ROE
-0.87
Return On Assets
-0.46
Return On Capital Employed
0.09
Net Income per EBT
0.87
EBT Per Ebit
-6.65
Ebit per Revenue
0.31
Effective Tax Rate
-0

Margins

Sales, General, & Administrative to Revenue
1.72
Research & Developement to Revenue
0.57
Stock Based Compensation to Revenue
0.07
Gross Profit Margin
0.36
Operating Profit Margin
0.31
Pretax Profit Margin
-2.04
Net Profit Margin
-1.78

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-14.81
Free CashFlow per Share
-14.81
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
-0.75
Return on Tangible Assets
-0.64
Days Sales Outstanding
36.39
Days Payables Outstanding
158.15
Days of Inventory on Hand
146.32
Receivables Turnover
10.03
Payables Turnover
2.31
Inventory Turnover
2.49
Capex per Share
0

Balance Sheet

Cash per Share
12,93
Book Value per Share
24,12
Tangible Book Value per Share
16.1
Shareholders Equity per Share
19.15
Interest Debt per Share
2.85
Debt to Equity
0.01
Debt to Assets
0.01
Net Debt to EBITDA
0.39
Current Ratio
4.1
Tangible Asset Value
0,01 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
8171000
Working Capital
0,00 Bil.
Intangibles to Total Assets
0.29
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
701000
Debt to Market Cap
0.14

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

SciSparc Ltd. Dividends
Year Dividends Growth

SciSparc Ltd. Profile

About SciSparc Ltd.

SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in soft gel capsule form. It also has an agreement with the Sheba Fund for Health Services and Research to examine the potential role of SCI-210 for the treatment of status epilepticus; and The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

CEO
Mr. Itschak Shrem
Employee
3
Address
Tower A
Tel Aviv, 6971916

SciSparc Ltd. Executives & BODs

SciSparc Ltd. Executives & BODs
# Name Age
1 Dr. Adi Zuloff-Shani Ph.D.
Chief Technologies Officer
70
2 Mr. Itschak Shrem
President & Director
70

SciSparc Ltd. Competitors